DGX Quest Diagnostics, Inc.

$DGX Q3 adjusted EPS came in at 3.00 dollars, up 15%, vs the 2.85 dollar consensus, on revenue of 3.097 billion dollars, up 10%. Fifth straight beat. Volume is doing the work though. Requisitions rose 14.5% while revenue per requisition fell 4.2%, and reported operating margin still expanded to 15.5% from 13.7%. Full year guide raised too, revenue to 12.065 to 12.105 billion dollars and adjusted EPS to 11.25 to 11.35 dollars.

$DGX Follow-up: Quest says unauthorized party accessed certain patient records. 🏢 Lab tester serving one in three adult Americans a year; $26.37B market value at $238.93, 16:00 ET Oct 21, 2026 ⚠️ Oct 22 Q3 release cited this incident: Quest learned Oct 21 of unauthorized access to Quanum LSM, a system some clients use to order tests; full scope under investigation 📈 Same-day Q3 release raised 2026 revenue guidance to $12.065B–$12.105B; neither filing gives a cost estimate for the incident 📅 Next: No date given for findings on the full scope Source: SEC 8-K, Oct 22 + Q3 release, Oct 22

QUEST DIAGNOSTICS $DGX Q3’26 EARNINGS HIGHLIGHTS - Revenue: $3.10B (Est. $3.05B) 🟢; +10.0% YoY - Adj. EPS: $3.00 (Est. $2.86) 🟢; +15.4% YoY - GAAP EPS: $2.78; +28.7% YoY

$DGX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $3.00 up 15.38% YoY • Reported revenue of $3.1B up 9.98% YoY • Quest Diagnostics raised full year 2026 net revenue guidance to between $12.07B and $12.11B, reported diluted EPS to $10.21-$10.31, and adjusted diluted EPS to $11.25-$11.35.

$DGX Quest lifts 2026 adjusted EPS guide to $11.25-$11.35 from $11.05-$11.25. 🏢 Lab tester Quest Diagnostics: $26.37B market value at $238.93, 16:00 ET Oct 21, 2026 📉 Q3 revenue per requisition fell 4.2%, even as requisitions rose 14.5% and revenue grew 10.0% to $3.097B 🚀 2026 revenue guide now $12.065B-$12.105B, from $11.95B-$12.05B ⚠️ Risk factors cite an incident described in a separate Oct 22 8-K that the release does not explain 📅 Next: 2027 Investor Day on March 25, 2027, at the New York Stock Exchange Source: PR Newswire release + SEC 8-K, Oct 22

$DGX Reports Thursday before the open. Consensus is 2.85 dollars EPS, up 9.6% year over year, on 3.04 billion dollars in revenue, up 8.1% (Zacks). That EPS mark is still below the 3.12 dollars it actually posted in Q2, and estimates have not moved in 30 days. It has beaten in each of the last four quarters, average surprise 5.77%.

Quest Diagnostics shares could move 4.4% when the company reports earnings on October 22 before the market opens, according to Bloomberg options data. The stock has exceeded its options-implied move in seven of its last eight earnings announcements, suggesting that options markets have frequently underestimated the magnitude of its post-earnings price swings. Recent reactions highlight this pattern. On July 23, shares moved 13.0%, compared with an implied move of just 2.6%, while on April 21, the stock moved 6.3% versus 3.5% expected. On February 10, shares fluctuated 11.0%, compared with an options-implied move of 4.0%. The only exception in the recent series occurred on October 21, 2025, when the stock moved 1.0%, below the implied 3.9%. Other earnings reactions included a 5.9% move versus 1.9% implied on July 22, 2025; 2.9% versus 1.8% on April 22, 2025; and 8.4% versus 4.0% on January 30, 2025. On October 22, 2024, shares moved 5.7%, compared with an implied 4.8%. $DGX

$DGX $UNH Sector rotation pulling these 2 down a bit Both are best in class within their sub section of healthcare. Good buying op for both